Sonnet BioTherapeutics Holdings, Inc. Logo

Sonnet BioTherapeutics Holdings, Inc.

Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.

SONN | US

Overview

Corporate Details

ISIN(s):
US83548R1059
LEI:
Country:
United States of America
Address:
100 OVERLOOK CENTER, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic medicines. The company's core technology is its proprietary Fully Human Albumin-Binding (FHAB™) platform, which utilizes a single-chain antibody fragment (scFv) that binds to the body's own albumin. This 'hitch-hiking' mechanism is designed to deliver cytokine payloads directly to tumor tissues, enhancing drug penetration, retention, and local activation. Sonnet's therapeutic goal is to convert immunologically 'cold' tumors into 'hot' tumors, thereby making them more responsive to treatment. The company's pipeline consists of several cytokine-derived therapeutic candidates in clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sonnet BioTherapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonnet BioTherapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sonnet BioTherapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Phio Pharmaceuticals Corp. Logo
Developing RNAi-based immuno-oncology therapeutics for melanoma and other skin cancers.
United States of America
PHIO
Phoenix Asia Holdings Ltd Logo
A subcontractor for substructure projects and a large-scale manufacturer of fine chemicals & APIs.
United States of America
PHOE
Photocure ASA Logo
Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.
Norway
PHO
Pierrel Logo
Global pharma company specializing in dental anesthetics and contract manufacturing services.
Italy
PRL
PLIANT THERAPEUTICS, INC. Logo
Developing novel integrin-based therapies for fibrosis and related diseases.
United States of America
PLRX
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea
222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel
PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America
PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America
PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea
041910

Talk to a Data Expert

Have a question? We'll get back to you promptly.